Patents Examined by Jayme A. Huleatt
  • Patent number: 4946781
    Abstract: A recombinant DNA molecule comprising a plasmid vector having operationally inserted therein a gene coding for homoserine kinase is disclosed along with bacteria containing this recombinant DNA molecule and methods of using these bacteria to produce amino acids in large quantities.
    Type: Grant
    Filed: February 3, 1988
    Date of Patent: August 7, 1990
    Assignee: Ajinomoto Co., Inc.
    Inventors: Shigeru Nakamori, Hiroshi Takagi, Masaaki Ishida, Takaaki Sato, Kiyoshi Miwa, Konosuke Sano
  • Patent number: 4943531
    Abstract: This invention provides a plasmic which, when introduced into a suitable host cell and grown under appropriate conditions, effects expression of a gene on the plasmid and production of a polypeptide having reverse transcriptase activity. The plasmid is a double-stranded DNA molecule which includes in a 5' to 3' order the following: a DNA sequence which includes an inducible promoter; a DNA sequence which includes an ATG initiation condon; the central portion of the Moloney murine leukemia virus (MuLV) pol gene, said central portion including a DNA sequence which encodes the polypeptide having reverse transcriptase activity; a DNA sequence which contains a gene associated with a selectable or identifiable phenotypic trait which is manifested when the vector is present in the host cell; and a DNA sequence which contains an origin of replication from a bacterial plasmid capable of autonomous replication in the host cell.
    Type: Grant
    Filed: May 6, 1985
    Date of Patent: July 24, 1990
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Stephen P. Goff, Naoko Tanese, Monica J. Roth
  • Patent number: 4942125
    Abstract: Cloning and expression vectors for hepatitis B HBxAg, cell cultures containing those vectors, polypeptides related to HBxAg and diagnostic systems and methods for assaying for the presence of HBxAg and anti-HBxAg antibodies in a body sample are disclosed.
    Type: Grant
    Filed: May 26, 1987
    Date of Patent: July 17, 1990
    Assignee: Scripps Clinic and Research Foundation
    Inventor: Ann M. Moriarty
  • Patent number: 4937195
    Abstract: An undifferentiated symbiotic combination of lichen flora induced from a tissue of lichen flora and having a capability of producing any lichenous substance.
    Type: Grant
    Filed: May 27, 1986
    Date of Patent: June 26, 1990
    Assignee: Nippon Paint Co., Ltd.
    Inventors: Yoshikazu Yamamoto, Ryuzo Mizuguchi, Yasuyuki Yamada
  • Patent number: 4935364
    Abstract: This invention relates to a method of isolating deletion mutants of Vibrio cholerae, wherein the deletion is predetermined by digestion with restriction endonucleases of known specificity. The deletions are inserted into the Vibrio cholerae chromosome by in vivo recombination betweem a plasmid carrying the desired deletion, with adjacent flanking sequences, and the Vibrio cholerae chromosome. The invention includes the isolation and characterization of a new Vibrio cholerae strain having a deletion in the tox gene, as defined by Acc I restriction endonuclease sites.
    Type: Grant
    Filed: June 5, 1989
    Date of Patent: June 19, 1990
    Assignee: Swiss Serum and Vaccine Institute Berne
    Inventors: James B. Kaper, Myron M. Levine
  • Patent number: 4935351
    Abstract: An oligopeptide is prepared by use of a vector wherein DNA coding for the intended oligopeptide has been introduced into a plasmid including a leader gene and an alpha-amylase structural gene.
    Type: Grant
    Filed: July 18, 1985
    Date of Patent: June 19, 1990
    Assignees: Kunio Yamane, Daicel Chemical Industries, Ltd., The Calpis Food Industry Co., Ltd., Oji Corn Starch Co., Ltd., Nissan Chemicals Industries, Ltd.
    Inventors: Kunio Yamane, Hisato Yamazaki, Kazutaka Ohmura, Teruaki Shiroza, Takashi Furusato
  • Patent number: 4929548
    Abstract: A process for producing GIF-2, an antimicrobial peptide, by culturing Bacillus cereus, FERM BP-746, under conditions sufficient to produce GIF-2 and recovering GIF-2 from the culture medium.
    Type: Grant
    Filed: December 2, 1987
    Date of Patent: May 29, 1990
    Assignee: Kibun Co., Ltd.
    Inventors: Sachio Wakayama, Fumiyasu Ishikawa, Kunio Oishi
  • Patent number: 4927758
    Abstract: Disclosed is a process for producing histidine by transforming a host microorganism belonging to the genus Corynebacterium or Brevibacterium with a recombinant DNA of a DNA fragment containing a gene involved in the biosynthesis of histidine and a vector DNA, culturing the transformant in a nutrient medium, accumulating histidine in the culture medium and recovering histidine therefrom.
    Type: Grant
    Filed: August 25, 1987
    Date of Patent: May 22, 1990
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Toru Mizukami, Ryoichi Katsumata, Tetsuo Oka
  • Patent number: 4925799
    Abstract: A plasmid cloning vector containing both transcriptional and translational regulatory sequences derived from the bacteriophage lambda genome was constructed to achieve high level expression of prokaryotic and eukaryotic genes. The system utilizes a plasmid vehicle carrying the strong, regulatable lambda promoter, P.sub.L, and host lysogens into which this vector can be stabily transformed. The lysogen synthesizes sufficient repressor (cI) to control P.sub.L expression and thereby stabilize plasmids which carry such a highly efficient promoter. Use of a temperature sensitive repressor permits simple, rapid induction of P.sub.L transcripts at any given time. Efficient transcription of essentially any coding sequence is assured by providing the phage lambda antitermination factor, N, and a site on the transcription unit for its utilization (Nut site). This pAS1 plasmic closely resembles the earlier constructed pKC30cII, also a regulatory protein which activates promoters for lysogenic development.
    Type: Grant
    Filed: January 16, 1986
    Date of Patent: May 15, 1990
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Martin Rosenberg
  • Patent number: 4923818
    Abstract: The cDNA clone representing the full size human type IV collagenase (gelatinase) is disclosed.
    Type: Grant
    Filed: May 15, 1989
    Date of Patent: May 8, 1990
    Assignee: Washington University
    Inventors: Gregory I. Goldberg, Arthur Z. Eisen
  • FSH
    Patent number: 4923805
    Abstract: Biologically active heterodimeric human FSH composed of an alpha subunit and a beta subunit, each subunit being synthesized by a cell having an expression vector containing heterologous DNA encoding the subunit.
    Type: Grant
    Filed: January 30, 1985
    Date of Patent: May 8, 1990
    Assignee: Integrated Genetics, Inc.
    Inventors: Vemuri B. Reddy, Nancy Hsiung, Anton K. Beck, Edward G. Berstine
  • Patent number: 4920048
    Abstract: A method for stabilization of extra-chromosomal elements in bacteria during cultivation which comprises transformation of a host bacterium having a defect in a chromosomal gene needed for the synthesis or maintenance of the cell envelope with an extra-chromosomal element capable of complementing the chromosomal gene defect of the host bacterium, the extra-chromosomal element also including an expressible DNA-sequence coding for a desired product.
    Type: Grant
    Filed: December 10, 1985
    Date of Patent: April 24, 1990
    Assignee: Novo Industri A/S
    Inventor: Borge K. Diderichsen
  • Patent number: 4916071
    Abstract: Hybrid, third generation, plasminogen activators containing plural, heterologous polypeptide kringles prepared by recombinant DNA techniques as well as the genes coding for the activators, Vectors containing those genes and a method for using the plasminogen activators as thrombolytic agents, are disclosed.
    Type: Grant
    Filed: July 11, 1986
    Date of Patent: April 10, 1990
    Assignee: American Home Products Corporation
    Inventors: Paul P. Hung, Narender K. Kalyan, Shaw-guang L. Lee
  • Patent number: 4912046
    Abstract: Shuttle vector systems are provided for the regulated expression of subject genes in transformed hosts. A promoter/operator which does not originate with the transformed host cell controls expression of the subject gene and a repressor, which also does not originate with the host cell, regulates the promoter/operator. According to this invention, promoter/operator--repressor functionalities from one bacterium are used in other bacteria, thereby obviating the need to locate homologous expression regulatory sequences for each bacterial host.
    Type: Grant
    Filed: June 8, 1987
    Date of Patent: March 27, 1990
    Assignee: Genentech, Inc.
    Inventors: Dennis J. Henner, Daniel G. Yansura
  • Patent number: 4908312
    Abstract: The invention relates to a bacterial process for producing phenylalanine. The process utilizes a Corynebacterium or Brevibacterium host which is transformed with a recombinant DNA. The recombinant DNA harbors a DNA containing a gene which encodes chorismate mutase or prephenate dehydratase. The transformed microorganism is then cultured in order to accumulate phenylalanine in the culture medium and the phenylalanine is recovered therefrom.
    Type: Grant
    Filed: December 7, 1988
    Date of Patent: March 13, 1990
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Akio Ozaki, Ryoichi Katsumata, Tetsuo Oka
  • Patent number: 4908316
    Abstract: An antibiotic has been isolated from fermentation of a new Streptomyces culture. The new ionophore is active as an antibacterial and anticoccidial agent.
    Type: Grant
    Filed: February 29, 1988
    Date of Patent: March 13, 1990
    Assignee: Pfizer Inc.
    Inventors: Walter P. Cullen, John R. Oscarson, Junsuke Tone, Hiroshi Maeda
  • Patent number: 4908204
    Abstract: A fibrinolytically active hybrid protein which comprises one chain of a 2-chain protease linked to a chain of a different 2-chain protease, or to the same chain of the same protease, at least one of the chains in the hybrid protein being derived from a fibrinolytically active protease, such that the hybrid protein has a catalytic site essential for fibrinolytic activity which is optionally blocked by a removable blocking group.
    Type: Grant
    Filed: February 22, 1988
    Date of Patent: March 13, 1990
    Assignee: Beecham Group p.l.c.
    Inventors: Jeffery H. Robinson, Ian Dodd
  • Patent number: 4900674
    Abstract: A phosphorous-containing analog-ligand having a conformation that substantially corresponds to the conformation of an amide- or ester-forming transition state is used to induce production of receptor molecules whose antibody combining sites have amide or ester synthase catalytic activity when reacted with a ligand containing (i) a carbonyl carbon atom and (ii) an amine or alcohol group that are structurally capable of forming a preselected carboxylic amide or ester bond.
    Type: Grant
    Filed: May 28, 1987
    Date of Patent: February 13, 1990
    Assignee: Scripps Clinic and Research Foundation
    Inventors: Stephen Benkovic, Richard A. Lerner, Alfonso Tramontano, Andrew D. Napper
  • Patent number: 4898825
    Abstract: A mixture containing a single-chain tissue plasminogen activator (tPA) and/or double-chain tPA is brought into close contact with a column carrying an immobilized Erythrina trypsin inhibitor as an affinity agent. Adsorbed protiens are eluted with eluents having different pHs with or without arginine or benzamidine, so that single-chain tPA is obtained in the eluent with a pH at least 4.5 and double-chain tPA is obtained in the eluent with a pH lower than 4.5.
    Type: Grant
    Filed: April 29, 1987
    Date of Patent: February 6, 1990
    Assignee: Mitsui Toatsu Chemicals, Incorporated
    Inventors: Mitsuyoshi Morii, Masaharu Ohoka, Toshihiko Suzuki, Katsuyuki Suzuki, Nobuhiro Kawashima, Noriko Morii, Kunizo Mori
  • Patent number: 4895718
    Abstract: A serotype 2 Marek's disease vaccine comprising a cloned strain designated as 301B/1 has been derived from a field isolate. This strain is characterized by superior levels of replicative ability and protectivity in chickens as compared to existing commercial serotype 2 strains, and it is virtually nonpathogenic. 301B/1 is particularly useful in the formulation of highly efficacious bivalent and polyvalent vaccines.
    Type: Grant
    Filed: July 10, 1987
    Date of Patent: January 23, 1990
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventor: Richard L. Witter